These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1677 related items for PubMed ID: 25708133

  • 1. Prevalence and risk factors for biopsy-proven non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in a prospective cohort of adult patients with gallstones.
    García-Monzón C, Vargas-Castrillón J, Porrero JL, Alonso MT, Bonachía O, Castillo MJ, Marcos A, Quirós E, Ramos B, Sánchez-Cabezudo C, Villar S, Sáez A, Rodríguez de Cía J, del Pozo E, Vega-Piris L, Soto-Fernández S, Lo Iacono O, Miquilena-Colina ME.
    Liver Int; 2015 Aug; 35(8):1983-91. PubMed ID: 25708133
    [Abstract] [Full Text] [Related]

  • 2. Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design.
    Xu ZJ, Shi JP, Yu DR, Zhu LJ, Jia JD, Fan JG.
    Adv Ther; 2016 Nov; 33(11):2069-2081. PubMed ID: 27743352
    [Abstract] [Full Text] [Related]

  • 3. Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
    Otgonsuren M, Estep MJ, Hossain N, Younossi E, Frost S, Henry L, Hunt S, Fang Y, Goodman Z, Younossi ZM.
    J Gastroenterol Hepatol; 2014 Dec; 29(12):2006-13. PubMed ID: 25039333
    [Abstract] [Full Text] [Related]

  • 4. A non-invasive prediction model for non-alcoholic steatohepatitis in paediatric patients with non-alcoholic fatty liver disease.
    Eng K, Lopez R, Liccardo D, Nobili V, Alkhouri N.
    Dig Liver Dis; 2014 Nov; 46(11):1008-13. PubMed ID: 25106814
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
    Verma S, Jensen D, Hart J, Mohanty SR.
    Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Prevalence of biopsy-proven non-alcoholic fatty liver disease in severely obese subjects without metabolic syndrome.
    Qureshi K, Abrams GA.
    Clin Obes; 2016 Apr; 6(2):117-23. PubMed ID: 26856683
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. FICK-3 Score Combining Fibrosis-4, Insulin Resistance and Cytokeratin-18 in Predicting Non-alcoholic Steatohepatitis in NAFLD Egyptian Patients.
    Mohammed MA, Omar NM, Mohammed SA, Amin AM, Gad DF.
    Pak J Biol Sci; 2019 Jan; 22(10):457-466. PubMed ID: 31930835
    [Abstract] [Full Text] [Related]

  • 15. A Comparison of Brunt's Criteria, the Non-Alcoholic Fatty Liver Disease Activity Score (NAS), and a Proposed NAS Scoring that Includes Fibrosis in Non-Alcoholic Fatty Liver Disease Staging.
    Santiago-Rolón A, Purcell D, Rosado K, Toro DH.
    P R Health Sci J; 2015 Dec; 34(4):189-94. PubMed ID: 26602577
    [Abstract] [Full Text] [Related]

  • 16. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis.
    Koo BK, Kim D, Joo SK, Kim JH, Chang MS, Kim BG, Lee KL, Kim W.
    J Hepatol; 2017 Jan; 66(1):123-131. PubMed ID: 27599824
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease.
    Nascimbeni F, Bedossa P, Fedchuk L, Pais R, Charlotte F, Lebray P, Poynard T, Ratziu V, LIDO (Liver Injury in Diabetes and Obesity) Study Group.
    J Hepatol; 2020 May; 72(5):828-838. PubMed ID: 31862486
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Hepatic artery resistive index (HARI) and non-alcoholic fatty liver disease (NAFLD) fibrosis score in NAFLD patients: cut-off suggestive of non-alcoholic steatohepatitis (NASH) evolution.
    Tana C, Tana M, Rossi S, Silingardi M, Schiavone C.
    J Ultrasound; 2016 Sep; 19(3):183-9. PubMed ID: 27635163
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 84.